GSDMA and neuropathy: Translational progress is hindered by systemic heterogeneity across neuropathy subtypes (metabolic, traumatic, vascular), overlapping death pathway activation, and a stark clinical translation gap—exemplified by the absence of trials targeting pyroptosis biomarkers (ASC specks, gasdermin cleavage) or NLRP3 antagonists like dapansutrile [257].